Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Arcutis Biotherapeutics director Howard G. Welgus reported an open-market sale of 10,000 shares of Common Stock at a weighted average price of $23.8801 per share. After this transaction, he directly holds 39,744 shares of Arcutis common stock.
The sale on April 1, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. The shares were sold in multiple trades at prices ranging from $23.61 to $24.12 per share.
Arcutis Biotherapeutics (ARQT) reported proposed sales of Common Stock under a Form 144 by Howard Welgus. The filing lists two recent dispositions: 10,000 shares sold on 03/02/2026 for $256,517.50 and 10,000 shares sold on 02/02/2026 for $250,482.69. The notice also references 10,000 shares tied to a prior stock option exercise on 06/04/2018.
Arcutis Biotherapeutics Inc ownership update: The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock, representing 0%. The filing cites an internal realignment on January 12, 2026 and disaggregation of subsidiary holdings in accordance with SEC Release No. 34-39538.
The form is signed by Ashley Grim, Head of Global Fund Administration, on March 26, 2026.
Arcutis Biotherapeutics director Leonard Keith R reported a mix of stock option exercises and share sales in Arcutis Biotherapeutics, Inc. He exercised fully vested stock options for 27,052 and 12,220 shares of common stock at exercise prices of $8.63 and $7.51 per share, respectively, on March 2, 2026. On the same day, he sold 39,272 shares of common stock in open-market transactions at a weighted average price of $25.392 per share, under a Rule 10b5-1 trading plan adopted on November 18, 2025 with an end date of February 16, 2027. After these transactions, he directly owned 22,123 Arcutis shares and an additional 1,750 shares were held indirectly by the Leonard Family Trust, for which he is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock in an open-market transaction. The sale took place on March 2, 2026 at a weighted average price of $25.6518 per share, in multiple trades between $25.37 and $26.10. After this sale, he directly owned 49,744 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025 with an end date of May 29, 2026.
Arcutis Biotherapeutics officer Larry Todd Edwards reported both stock sales and new equity awards. On March 2, 2026, he executed open-market sales totaling 3,687 shares of common stock at weighted average prices around the mid‑$20s per share to cover tax withholding obligations tied to vested restricted stock units.
On February 27, 2026, he received a grant of 77,000 stock options and a separate award of 30,000 restricted stock units, both at a reported price of $0.0000 per share. Following these transactions, his direct common stock holdings were reported at 175,178 shares, and the new options will vest monthly over four years starting March 1, 2026.
Arcutis Biotherapeutics director and officer Todd Watanabe reported a mix of stock sales and new equity awards. On March 2, 2026, he sold a total of 37,349 shares of common stock in open-market transactions at weighted average prices of $25.1606 and $25.9139 per share. A footnote states these shares were sold to cover tax withholding obligations related to vesting restricted stock units (RSUs).
On February 27, 2026, he received an option covering 266,000 shares, vesting monthly over four years starting March 1, 2026, and a grant of 102,000 RSUs, vesting 25% annually each March 1 beginning in 2027. The filing also notes additional shares held by several trusts and an LLC, for which he disclaims beneficial ownership beyond any pecuniary interest.
Arcutis Biotherapeutics executive Masaru Matsuda reported a mix of stock sales and equity awards. On March 2, 2026, he sold a total of 12,058 shares of common stock in open-market transactions at weighted average prices around $25–$26, under a Rule 10b5-1 trading plan ending on September 4, 2026. Some sales are described as covering tax withholding obligations from restricted stock unit vesting. Following these sales, he continued to hold over 130,000 shares directly.
On February 27, 2026, Matsuda received equity compensation, including 97,000 stock options and 37,000 restricted stock units. The options vest monthly over four years starting March 1, 2026, and the RSUs vest 25% annually each March 1 beginning in 2027, contingent on continued service to the company.
Arcutis Biotherapeutics, Inc. SVP and Chief Financial Officer Latha Vairavan reported both stock awards and small share sales. On February 27, 2026, she received grants of 27,000 Restricted Stock Units (RSUs), each convertible into one common share, vesting 25% annually starting March 1, 2027, and a stock option for 70,000 shares that vests monthly over four years from March 1, 2026.
On March 2, 2026, she sold a total of 2,853 common shares in open‑market transactions at weighted average prices of $25.1605 and $25.9140 per share, in price ranges disclosed in the footnotes, to cover tax‑withholding obligations upon RSU vesting. After these sales, she directly held 87,754 common shares.
Arcutis Biotherapeutics insider equity activity mixes sales and new awards. Officer Patrick Burnett sold 6,106 and 181 shares of common stock on March 2, 2026 at weighted average prices of $25.1604 and $25.9140. A footnote explains these sales were made to cover tax withholding obligations from vesting restricted stock units, rather than discretionary open‑market selling.
Burnett also received equity compensation on February 27, 2026, including a stock option grant for 77,000 shares and a 30,000‑share restricted stock unit award, both with no cash exercise or purchase price at grant. Another entry reflects 16,750 RSUs tied to an earlier performance grant whose milestone was certified on August 18, 2022. A separate footnote notes a prior reporting error that understated his beneficial ownership by 18 to 36 shares, now corrected.